TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34472200
Drug: 5‐mg flunarizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐mg flunarizine hydrochloride capsules (test) with high-fat meals
Study: 34472200
Drug: 5‐mg flunarizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐mg flunarizine hydrochloride capsules (reference)
Study: 36097005
Drug: Urate-lowering therapies
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urate-lowering therapies (ULT) - allopurinol and febuxostat, treated during at least 75% of the study period (PT ≥ 75; n=51)
Study: 36097005
Drug: Urate-lowering therapies
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urate-lowering therapies (ULT) - treated less than 75% of the study period (PT < 75; n=31)
Study: 33583034
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of dexamethasone (12 mg)
Study: 33583034
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of dexamethasone (6 mg)
Study: 35899336
Drug: General anesthesia+ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: General anesthesia+ibuprofen suppository
Study: 35899336
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination (general anesthesia + lidocaine + ibuprofen suppository)
Study: 32565008
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day methylphenidate
Study: 35047059
Drug: Autoimmune cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoimmune cell therapy
Study: 35965423
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy (GDFT) guided by a hemodynamic monitoring system
Study: 35965423
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid therapy based on mean arterial pressure and diuresis
Study: 35677096
Drug: Routine drugs
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drugs combined with cardiac rehabilitation for 6 months
Study: 35659704
Drug: High-dose IFNα
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFNα (HDI)
Study: 34391270
Drug: Sling-based manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sling-based manual therapy applied to the cervicothoracic junction (C7-T3) and upper cervical spine (C0-C1).
Study: 32487236
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg) administered 3 times/week for 3 or 4 weeks
Study: 32487236
Drug: Ketamine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine maintenance (weekly infusions for 1 month, then bi-weekly for 2 months, and finally monthly for 3 months)
Study: 35931989
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg dexmedetomidine as a perineural adjuvant
Study: 35931989
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 mL 0.5% ropivacaine without dexmedetomidine)
Study: 35931989
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg dexmedetomidine
Study: 34808751
Drug: Bulleyaconitine A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulleyaconitine A tablets combined with gabapentin
Study: 34808751
Drug: Bulleyaconitine A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulleyaconitine A tablets
Study: 32276179
Drug: Paclitaxel (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (90 mg/m2 on days 1, 8, 15) plus Bevacizumab (10 mg/kg on days 1, 15) every 28 days
Study: 32276179
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) every 21 days
Study: 35093535
Drug: Intravenous triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous triiodothyronine (T3) supplementation
Study: 32325038
Drug: ChAdOx1 MERS
Normalized name: mersalyl
DrugBank: Mersalyl (DB09338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 MERS (all doses)
Study: 32325038
Drug: ChAdOx1 MERS
Normalized name: mersalyl
DrugBank: Mersalyl (DB09338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 MERS (high-dose)
Study: 33270026
Drug: WeChat intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WeChat intervention providing breastfeeding knowledge and promotion information weekly from third month of pregnancy to 6 months postpartum
Study: 34543474
Drug: Proactive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive management with Cal/BD foam (twice weekly)
Study: 34543474
Drug: Reactive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive management with vehicle foam (twice weekly)
Study: 34543474
Drug: Cal/BD foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal/BD foam (once daily) during initial 4-week phase
Study: 34023810
Drug: Fenfluramine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (0.2 mg/kg/day, titrated to maximum 26 mg/day)
Study: 34426012
Drug: Sodium-glucose cotransporter
Normalized name: glucose / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-glucose cotransporter 2 inhibitors (SGLT2is)
Study: 35590054
Drug: Intravitreal ziv-aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ziv-aflibercept (IVZ) 1.25 mg/0.05 ml
Study: 33449919
Drug: Exendin(9-39)NH2 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exendin(9-39)NH2 infusion during acarbose treatment
Study: 33449919
Drug: Exendin(9-39)NH2 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exendin(9-39)NH2 infusion during placebo treatment
Study: 32320843
Drug: Brief advice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief advice combined with 1-week sample of nicotine replacement therapy (NRT) and active referral to smoking cessation services
Study: 32281219
Drug: Steroid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid administration in perinatal centers
Study: 35856361
Drug: L-carnitine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (15 g/bag, orally, twice a day)
Study: 35856361
Drug: CoQ10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (10 mg tablet orally, thrice daily) with Vitamin E (100 mg tablet orally, thrice daily)
Study: 33032778
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for atorvastatin
Study: 32961034
Drug: Macimorelin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macimorelin 2.0 mg/kg
Study: 32358608
Drug: Online Acceptance
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Acceptance and Commitment Therapy
Study: 34359042
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of 1.0 g/kg of 20% mannitol (immediately after anesthesia induction)
Study: 34359042
Drug: Routine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine administration of 1.0 g/kg of 20% mannitol (at the time of skin incision)
Study: 34359042
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of 1.0 g/kg of 20% mannitol
Study: 34359042
Drug: Routine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine administration of 1.0 g/kg of 20% mannitol
Study: 34548383
Drug: Burosumab 1
Normalized name: Burosumab 10 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burosumab 1 mg/kg every 4 weeks for 24 weeks
Study: 34548383
Drug: Burosumab 1
Normalized name: Burosumab 10 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burosumab 1 mg/kg every 4 weeks until week 96
Study: 32622071
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU daily cholecalciferol
Study: 32622071
Drug: 3750 IU
Normalized name: Ascorbic Acid/Beta Carotene/Catalase/Cysteine/Glutathione/L-Taurine/Manganese/Orgotein/Selenium/Vitamin A/Vitamin E/Zinc 250 MG-3750 IU-25 MG-25 MG-6.25 MG-50 MG-2 MG-50 MG-0.05 MG-1250 IU-100 IU-7.5 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3750 IU daily cholecalciferol
Study: 33647273
Drug: Daily acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily acute intermittent hypoxia combined with walking practice (AIH + WALK)
Study: 36201607
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine oral rinse
Study: 36201607
Drug: Saline oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline oral rinse
Study: 35800017
Drug: Neurocognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognitive Remediation Therapy (NCRT)
Study: 34772324
Drug: Sugar (glucose)
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar (glucose) solution
Study: 34772324
Drug: Non-nutritive sweetener
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nutritive sweetener (aspartame) solution
Study: 34029328
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure (PE) therapy, provided within 72 hours after a traumatic event, consisting of three sessions.
Study: 35475921
Drug: External pneumatic
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External pneumatic compression (EPC) treatment (110 mmHg)
Study: 35475921
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control (CTL)
Study: 33246873
Drug: Individualized self‐management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized self‐management combined with physical therapy
Study: 32046753
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) applied once within 48 hours of menstruation at six abdominal myofascial trigger points.
Study: 34348351
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IVAI) treat-and-extend (T&E)
Study: 34348351
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IVAI) T&E plus sham photodynamic therapy (PDT)
Study: 34348351
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IVAI) T&E plus standard fluence PDT with verteporfin
Study: 34348351
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IVAI) T&E
Study: 34348351
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IVAI) T&E plus sham PDT
Study: 33633278
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 × 150 mg caffeine daily)
Study: 33633278
Drug: Withdrawal (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal (3 × 150 mg caffeine for 8 days, then switch to placebo)
Study: 33633278
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 × placebo daily)
Study: 34171493
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training intervention (12 therapy sessions)
Study: 33624806
Drug: Elinzanetant 120
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elinzanetant 120 mg
Study: 33742316
Drug: Single intravesical
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravesical trigonal-only injection of OnabotulinumtoxinA
Study: 33742316
Drug: 20 trigone-sparing
Normalized name: TRIGONELLA FOENUM-GRAECUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 trigone-sparing injections of OnabotulinumtoxinA
Study: 33710268
Drug: Real-world evidence
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-world evidence studies on diabetes treatments
Study: 36122605
Drug: Nystatin oral
Normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin oral suspension (Control‐100,000IU/mL; 4 × /day)
Study: 33378447
Drug: 0.8% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% metronidazole gel
Study: 33378447
Drug: SMS reminder
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminder and placebo gel
Study: 34762534
Drug: Laser-Assisted Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-Assisted Drug Delivery (LADD) with 10% tranexamic acid solution
Study: 32818951
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate prescriptions
Study: 34921090
Drug: Cardiovascular preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiovascular preventive medication
Study: 32178668
Drug: Ropivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine alone (1 mg/kg)
Study: 32178668
Drug: Ropivacaine combined
Normalized name: bupivacaine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine combined with meloxicam (0.2 mg/kg)
Study: 33128351
Drug: Disease modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease modifying therapy
Study: 33128351
Drug: Observational studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observational studies on effectiveness of disease modifying treatments
Study: 36343847
Drug: Linerixibat 180
Normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linerixibat 180 mg once daily
Study: 36343847
Drug: Linerixibat 40
Normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linerixibat 40 mg twice daily
Study: 36343847
Drug: Linerixibat 90
Normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linerixibat 90 mg twice daily
Study: 36852705
Drug: Linerixibat (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linerixibat (various doses)
Study: 32618134
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg tablets for 24 weeks
Study: 36266431
Drug: Silymarin 140
Normalized name: silymarin 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 140 mg administered twice daily for 12 weeks
Study: 39388898
Drug: Pegvaliase treatment
Normalized name: pegvaliase
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegvaliase treatment
Study: 33121884
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine (10.9 mg of intrathecal 0.5% plain bupivacaine with 0.2 mg morphine)
Study: 33121884
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (10.9 mg of intrathecal 0.5% hyperbaric bupivacaine with 0.2 mg morphine)
Study: 32993573
Drug: Vagus Nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus Nerve Stimulation (VNS) Therapy
Study: 33799302
Drug: Stent retrievers
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent retrievers as primary treatment device
Study: 32236953
Drug: Licogliflozin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin (50 mg q.d.) with a 50% carbohydrate meal
Study: 32236953
Drug: Licogliflozin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin (50 mg q.d.) with a 0% carbohydrate meal
Study: 32236953
Drug: Psyllium 6
Normalized name: psyllium 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium 6 g or calcium carbonate 1 g supplementation
Study: 34560319
Drug: Twice-daily iTBS
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily iTBS (600 pulses)
Study: 34560319
Drug: Once-daily iTBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily iTBS (1200 pulses)
Study: 35153479
Drug: Combination low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination low-dose theophylline (100mg bd) and prednisone (5mg qd)
Study: 32910531
Drug: Tofacitinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (both doses)
Study: 33141883
Drug: Osteomyelitis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteomyelitis treatment
Study: 35712800
Drug: Bromocriptine quick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine quick release (BCQR) titrated from 0.8 mg to 1.6 mg to 3.2 mg (minimum dose 1.6 mg) for 4 weeks
Study: 33978167
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe with 0 mg folic acid
Study: 33978167
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe with 0.4 mg folic acid
Study: 33978167
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe with 2.8 mg folic acid
Study: 35652772
Drug: ACB‐IPACK block
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB‐IPACK block (30 mL bupivacaine 0.25%)
Study: 35652772
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block (ACB) (20 mL bupivacaine 0.25%)
Study: 36331326
Drug: Inclisiran (284
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (284 mg administered on Days 1, 90, and every 6 months thereafter for 18 months)
Study: 34126308
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation Therapy for Anhedonia (BATA)
Study: 34256199
Drug: Dual transcranial
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual transcranial direct current stimulation (dual tDCS) and modified constraint-induced movement therapy (mCIMT)
Study: 34256199
Drug: Sham dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham dual tDCS and modified constraint-induced movement therapy (mCIMT)
Study: 36104267
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate 250 mg
Study: 36104267
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate 500 mg
Study: 36104267
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate 1000 mg
Study: 36104267
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate 2000 mg
Study: 36104267
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (all doses)
Study: 33382916
Drug: LY2775240 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2775240 (20 mg)
Study: 33382916
Drug: Apremilast (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast (30 mg)
Study: 36013087
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg after induction and 15 min before the end of surgery)
Study: 33813948
Drug: Both options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both options (intensive lifestyle change and metformin)
Study: 34408675
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioral therapy (iCBT) plus treatment-as-usual (TAU)
Study: 37146874
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) only
Study: 33372439
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current therapy (IFC), active therapy, three times per week for four weeks
Study: 34791009
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (PSs) 2 g/d for 28 days
Study: 34567960
Drug: 4-weekly BTA
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4-weekly BTA treatment
Study: 34567960
Drug: 12-weekly BTA
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-weekly BTA treatment
Study: 35688164
Drug: tixagevimab–cilgavimab 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: tixagevimab–cilgavimab 600 mg (two consecutive 3 mL intramuscular injections, 300 mg tixagevimab and 300 mg cilgavimab)
Study: 35688164
Drug: tixagevimab–cilgavimab 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: tixagevimab–cilgavimab 600 mg
Study: 33271319
Drug: Micronized vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized vaginal progesterone (MVP) gel
Study: 36055978
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral ondansetron (0.33 mg twice daily)
Study: 36036121
Drug: Prednisone 2
Normalized name: prednisone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 2 mg/(kg·day) (maximum 60 mg) for 4 weeks
Study: 36036121
Drug: Prednisone 2
Normalized name: prednisone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 2 mg/(kg·day) (maximum 60 mg) for 6 weeks
Study: 36036121
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment for 4 weeks
Study: 36036121
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment for 6 weeks
Study: 36004653
Drug: Tirzepatide (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (5, 10, and 15 mg)
Study: 32291277
Drug: Tirzepatide (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (10, 15 mg)
Study: 35143800
Drug: Methotrexate 25
Normalized name: methotrexate 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 25 mg weekly
Study: 35143800
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 1.5 g twice daily